Methods for treating cancer resistant to erbb therapeutics

摘要

Provided herein are methods for treating cancer that is resistant to treatment with an anti- ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene 5 amplification. The methods involve administering to a subject a combination of an anti- ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or P13 kinase mediated signaling in a cancer cell.